MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
41.16
+2.15 (5.51%)
At close: Jun 2, 2025, 4:00 PM
48.99
+7.83 (19.02%)
After-hours: Jun 2, 2025, 7:59 PM EDT
MLTX Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for MLTX stock ranges from a low of $61 to a high of $104. The average analyst price target of $77.71 forecasts a 88.80% increase in the stock price over the next year.
Price Target: $77.71 (+88.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MLTX stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $61 | Hold → Buy | Upgrades | $61 | +48.20% | May 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +60.35% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +60.35% | Apr 30, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $67 | Buy | Initiates | $67 | +62.78% | Mar 18, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $82 → $73 | Strong Buy | Maintains | $82 → $73 | +77.36% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
1.13B
from 553.54M
Increased by 103.42%
Revenue Next Year
n/a
from 1.13B
EPS This Year
-2.96
from -1.89
EPS Next Year
-3.61
from -2.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 192.1M | ||
| Avg | n/a | n/a | 94.2M | ||
| Low | n/a | n/a | 45.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.29 | -0.76 | -2.61 | ||
| Avg | -2.96 | -3.61 | -3.91 | ||
| Low | -3.15 | -5.00 | -4.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.